> Germany's Vasopharm Biotech has closed its second round of venture capital with $11.8 million. Release
> Adolor says it will have to delay human studies of an experimental pain therapy after the FDA demanded more safety data and more input on the planned trial. Report
> Nuvelo of San Carlos, CA, has priced an offering of 6.5 million shares of common stock at $16 each. Release
> Cytori has received an $11 million milestone from its joint venture with Olympus. Release
> With its stock on the rebound, Schering-Plough says it's ready to go on the hunt for new acquisitions. Report
> SGX has cut the asking price on its IPO to $6 to $7 a share. Report
> Vyteris Holdings is cutting its work force by one-third. Release
> The FDA has granted fast track review status for Schering-Plough's oral hepatitis C protease inhibitor that is currently in Phase II. Report
> Vion Pharmaceuticals of New Haven, CT, plans to conduct a pivotal Phase II trial of its anticancer agent Cloretazine in elderly patients with acute myelogenous leukemia. Release
> AEterna Zentaris has regained the exclusive rights to its lead Luteinizing Hormone Releasing Hormone antagonist product candidate. Release
> Codexis will receive an undisclosed milestone payment from Bristol-Myers Squibb and has extended the terms of an earlier announced research agreement. Release
> GTx and Gen-Probe will collaborate on a research-stage diagnostic test. Release
And Finally... The New York Times examines how the drug industry lobbies in all 50 state legislatures, where drug initiatives are commonplace. Article